Previous Article | Next Article 
J Virol, February 1998, p. 1452-1461, Vol. 72, No. 2
Laboratory of Infectious Diseases, National
Institute of Allergy and Infectious Diseases, National Institutes
of Health, Bethesda, Maryland 20892-0720,1
and
Department of Immunology and Microbiology,
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois
606122
Received 11 August 1997/Accepted 16 October 1997
The NS1 protein (139 amino acids) is one of the two nonstructural
proteins of human respiratory syncytial virus (RSV) and is encoded by a
very abundant mRNA transcribed from the promoter-proximal RSV gene. The
function of NS1 was unknown and was investigated here by using a
reconstituted transcription and RNA replication system that involves a
minireplicon and viral proteins (N, P, L and M2-1) expressed from
separate cotransfected plasmids. Coexpression of the NS1 cDNA strongly
inhibited transcription and RNA replication mediated by the RSV
polymerase, even when the level of expressed NS1 protein was
substantially below that observed in RSV-infected cells. The effect
depended on synthesis of NS1 protein rather than NS1 RNA alone.
Transcription and both steps of RNA replication, namely, synthesis of
the antigenome and the genome, appeared to be equally sensitive to
inhibition. The efficiency of encapsidation of the plasmid-derived
minigenome was not altered by coexpression of NS1, indicating
that the inhibition occurs at a later step. In two different
dicistronic minigenomes, transcription of each gene was equally
sensitive to inhibition by NS1. This suggested that the gradient of
transcriptional polarity was unaffected and that the effect of NS1
instead probably involves an early event such as polymerase entry on
the genome. NS1-mediated inhibition of transcription and RNA
replication was not affected by coexpression of the M2 mRNA, which has
two open reading frames encoding the transcriptional elongation factor
M2-1 and the putative negative regulatory factor M2-2. The potent
nature of the NS1-mediated inhibition suggests that negative regulation
is an authentic function of the NS1 protein, albeit not necessarily the
only one.
Human respiratory syncytial virus
(RSV) is an important etiologic agent of severe lower respiratory tract
disease in infants and young children worldwide (7, 10). It
is the prototype member of the genus Pneumovirus of the
family Paramyxoviridae and has a single-stranded,
nonsegmented, negative-sense RNA genome of 15,222 nucleotides (nt).
RSV encodes 10 mRNAs and at least 10 (probably 11) distinct viral
proteins. Three RSV proteins are transmembrane surface glycoproteins: the attachment G protein, the fusion F protein, and the small hydrophobic SH protein of unknown function. An unglycosylated matrix M
protein is present as an inner virion protein. Three proteins associate
with genomic RNA to form the nucleocapsid: the major nucleocapsid
N protein, the P phosphoprotein, and the large L polymerase
subunit. The M2-1 protein, which is encoded by the upstream
translational open reading frame (ORF) of the M2 mRNA, has been shown
to be a transcription elongation factor and therefore probably also is
nucleocapsid associated (8, 9). The M2 mRNA contains a
second, conserved ORF called M2-2 that overlaps the first, which
encodes a putative negative regulatory activity and which therefore
appears to be an 11th RSV gene (9). Here, the two M2 ORFs
and their encoded proteins are referred to as M2-1 and M2-2 and the
mRNA containing both ORFs in their native configuration is called
M2(1+2). Finally, RSV encodes two nonstructural proteins, NS1 and
NS2, of unknown function. The RSV gene order is
3'-(leader)-NS1-NS2-N-P-M-SH-G-F-M2(1+2)-L-(trailer)-5' (7, 10). The M2-1, M2-2, NS1, and NS2 proteins lack
obvious counterparts in other nonsegmented negative-strand viruses.
The general features of RSV transcription and RNA replication resemble
those of the model nonsegmented negative-strand viruses Sendai virus
and vesicular stomatitis virus (24, 29). The genomic RNA is
tightly encapsidated both in the virion and intracellularly. The
polymerase enters the template at the 3'-terminal extragenic leader
region (21). Transcription involves a sequential stop-start mechanism that produces subgenomic mRNAs. Transcription is guided by
short conserved signals that flank each mRNA coding unit, namely, a
transcription gene start (GS) signal and a termination/polyadenylation gene end (GE) signal (21, 23). RNA replication occurs when the polymerase somehow switches to a readthrough mode in which the
transcription signals are not recognized. This results in the synthesis
of a positive-sense replicative intermediate, or antigenome, which also
is encapsidated. The N, P, and L proteins constitute the replicase,
whereas the transcriptase also requires the M2-1 elongation factor
(9, 17).
The NS1 and NS2 proteins are expressed from separate mRNAs encoded by
the first and second genes, respectively, that follow the 44-nt leader
region (6). Because of their promoter-proximal location,
these two mRNAs are the most abundant of the RSV transcripts (5). The NS1 protein is 139 amino acids long and is slightly acidic, but the predicted amino acid sequence provides no obvious clues
to its function. The NS1 and NS2 proteins each contain the same four
carboxy-terminal amino acids but otherwise are unrelated. Of the
various RSV proteins, NS1 (and NS2) exhibits an intermediate degree of
sequence conservation between the two human antigenic subgroups and
ovine or bovine RSV; it is more highly conserved than the SH or G
proteins but is less well conserved than any of the other proteins
(1, 20, 25).
We recently described a system in which RSV transcription and RNA
replication are reconstituted by the intracellular coexpression of an
RSV minireplicon and RSV proteins from separate transfected plasmids
(9, 14, 17). Here, we present evidence from this system that
the NS1 protein is a potent inhibitor of intracellular RSV
transcription and RNA replication.
cDNAs.
We previously described cDNAs encoding the C2 and C4
RSV-CAT minireplicons (17). The C2 RNA is 931-nucleotide
negative-sense minigenome analog of the RSV genome in which the
viral genes have been replaced by a negative-sense copy of the
chloramphenicol acetyltransferase (CAT) ORF flanked by GS and GE
signals and by the extragenic leader and trailer regions (Fig.
1) (17, 21-23). The C4 RNA is
a positive-sense mini-antigenome that is the complement of the C2
minigenome.
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
The NS1 Protein of Human Respiratory Syncytial
Virus Is a Potent Inhibitor of Minigenome Transcription and
RNA Replication
ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
View larger version (31K):
[in a new window]
FIG. 1.
Schematic representation (not to scale) of the
cDNA-encoded, negative-sense RSV-CAT C2 minigenome RNA and its
modified derivatives, MP13 and MP123. The C2 minigenome
contains the 3'-terminal 75 nt and 5'-terminal 179 nt of the genome of
RSV strain A2, including the leader, GS, non-protein-coding (NC), GE,
and trailer regions (open boxes). These sequences flank a
negative-sense copy of the CAT ORF (shaded box). MP13 is a version of
C2 in which a 35-nt sequence containing a GE signal, a
single-nucleotide intergenic region (IG), and GS signal has been
inserted in the CAT ORF at its BspEI site. This converts the
minigenome into one which is dicistronic, encoding two subgenic
CAT mRNAs of 271 and 495 nt, exclusive of poly(A). MP123 is a version
of C2 in which the first 34 nt of the leader region have been replaced
with a sequence that is complementary to the 5'-terminal 57 nt of the
trailer region (Tc) and thus contains the antigenome promoter. In
addition, MP13 and MP123 differ from C2 in each having a
single-nucleotide substitution in the trailer region that greatly
inhibits amplification by the RSV polymerase: in MP13 nt 5 from the 5'
end has been changed from G to A (TrG5A), and in MP123 nt 7 from the 5'
end has been changed from A to C (TrA7C). Nucleotide lengths of the
various segments are indicated.
Transfections. Confluent monolayers of 293 or HEp-2 cells (as indicated in the figure legends) in six-well dishes (each well contained 1.5 × 106 cells) were infected with recombinant vaccinia virus vTF7-3 expressing T7 RNA polymerase (15) at a multiplicity of infection of 10 PFU per cell. After 45 min of adsorption, the inoculum was replaced with 1 ml of Opti-MEM per well containing 10 µl of Lipofectamine or 12 µl of Lipofectace (Life Technologies) and amounts of minireplicon and N, P, and L plasmids as indicated in the figure legends. In some experiments, the standard plasmid mix also included the M2(1+2) or M2-1 (i.e., ORF 1 only) plasmid. The concentration of the NS1 plasmid was varied as indicated. In all experiments, pTM-1 vector plasmid lacking an insert was added to keep the total amount of plasmid transfected per well of cell monolayer constant. After 16 h of transfection, the transfection medium was replaced with 1.5 ml of Eagle's minimal essential medium containing 10% fetal bovine serum for 293 cells or Opti-MEM containing 2% fetal bovine serum for HEp-2 cells. The cells were typically harvested 24 h after the change of medium, i.e., 40 h postinfection.
Analysis of protein expression by Western blotting.
Typically, one-fifth of the volume of the total cells harvested from
one well was lysed in sodium dodecyl sulfate-polyacrylamide gel
electrophoresis sample buffer containing 
-mercaptoethanol, and about
1/150 of total cellular equivalent from a single well was run in each
lane of precast 4 to 20% gradient minigels (Novex) as specified by the
supplier. The gels were transferred onto Optitran (Schleicher & Schuell) nitrocellulose membranes with the buffer system of Towbin et
al. (28) at 250 mA for 2 h. The blots were washed in
TTBS (0.1 M Tris-HCl [pH 7.5], 0.5 M NaCl, 0.01% Tween 20) and
blocked in Blotto (5% [wt/vol] nonfat dry milk in TTBS) for 1 to
2 h before the specific antibody was added for overnight binding.
For detecting the N, P, and other structural proteins, a rabbit
antiserum against gradient-purified RSV virions was used (17). This antibody detected the G, F, N, P, M, M2-1, and SH proteins but not the NS1 and NS2 proteins. The NS1 and NS2 proteins were detected with a rabbit antiserum directed against a 10-amino-acid C-terminal peptide of NS2 protein. This antibody efficiently recognized both the NS1 and NS2 proteins in a Western blot, presumably because the
two proteins are identical for the C-terminal 4 amino acids. After
overnight incubation with the antibody, the blots were washed three
times for 10 min each in TTBS and then given a further incubation for
2 h in a secondary antibody solution prepared in Blotto containing 1 µg of goat anti-rabbit immunoglobulin conjugated to alkaline phosphatase per ml. The blots were washed three times for 10 min each
in TTBS lacking Tween 20 and then subjected to color development with
Nitro Blue Tetrazolium (NBT) and
5-bromo-4-chloro-3-indolylphosphate (BCIP) as specified by the
supplier (Promega).
CAT assay. Typically, 1/10 of the cells harvested from a single well was used to make 200 µl of cell lysate, and an aliquot of either 5 or 10 µl of lysate was used for the CAT assay. The CAT assay was based on the conversion of [14C]chloramphenicol to acetylated forms in the presence of acetyl coenzyme A as described before (16). The acetylated forms were separated by ascending thin-layer chromatography and visualized by autoradiography.
RNA isolation and Northern blot analysis. Total intracellular RNA was extracted by lysing the cell pellets in Trizol reagent (Life Technologies) as specified by the supplier, except that the RNAs were extracted twice with phenol-chloroform following isopropanol precipitation. The RNA samples were quantitated by spectrophotometry as well as by electrophoresis in agarose gels with ethidium bromide staining to ensure that the amounts of samples analyzed were equivalent. Total intracellular RNA samples (8 to 10 µg, representing one-fifth of the total amount from each well) were subjected to Northern blot analysis as described previously (4, 17). The radioactive signals on the blots were quantitated with a PhosphorImager (Molecular Dynamics) and were also exposed to X-ray film (Kodak X-AR).
Micrococcal nuclease treatment of intracellular RNA. Cells which had been infected with vTF7-3 and transfected with plasmids were harvested 40 h postinfection by scraping, washed once in phosphate-buffered saline, and lysed in 100 µl of 10 mM Tris-HCl (pH 7.5)-10 mM NaCl-1.5 mM MgCl2-10 mM CaCl2-1% Triton X-100-0.5% deoxycholate per well. An aliquot of each sample was treated with micrococcal nuclease (Nuclease S7; Boehringer Mannheim) at a final concentration of 20 µg/ml and incubated for 30 min at 30°C (2). RNA was isolated with Trizol reagent as described above.
| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
Expression of the NS1 protein in a reconstituted transcription and RNA replication system. We previously described a system in which RSV transcription and RNA replication are reconstituted intracellularly from transfected plasmids (9, 14, 17). The plasmids encode (i) minireplicon RNA, which can be a negative-sense analog of genomic RNA (called a minigenome) or a positive-sense analog of antigenomic RNA (a mini-antigenome), and (ii) the subset of RSV proteins necessary to reconstitute the RSV nucleocapsid and polymerase (9, 14, 17).
In the reconstituted system, coexpression of the N, P, and L proteins is necessary and sufficient for RSV RNA replication whereas processive transcription also requires expression of the M2-1 protein (9, 14, 17). The purpose of this study is to describe the effect of coexpression of the NS1 protein on RSV transcription and RNA replication. The system used conditions under which the levels of plasmid-expressed viral proteins were similar to those expressed by RSV infection, which should be an important factor for re-creating authentic effects. This is illustrated in Fig. 2 (upper panel), in which the levels of N and P expressed in RSV-infected cells (lane 1) were shown by Western blot analysis to be similar to those expressed from transfected N and P plasmids (lane 3). Similar findings have been described elsewhere, based on both Western blot analysis and radiolabeling (references 9, 14, 17 and unpublished data). Coexpression of incrementally increasing amounts of the NS1 plasmid resulted in concomitant increases in the expression of the NS1 protein, as detected by Western blot analysis (Fig. 2, lower panel, lanes 4 to 6) with an antipeptide rabbit serum that cross-reacts with the NS1 and NS2 proteins (see Materials and Methods) or by metabolic labeling with [35S]methionine, immunoprecipitation, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (data not shown). In RSV-infected cells, the NS1 protein could be readily detected by Western blot analysis at 8 h postinfection and was expressed at maximal levels between 16 and 24 h postinfection (data not shown). The maximum level of NS1 protein expressed during RSV infection was similar to the amount expressed in response to 100 ng of transfected plasmid (Fig. 2). The expression of the NS1 protein from the transfected plasmid had no effect on the expression of the N, P, or M2-1 proteins from cotransfected plasmids (Fig. 2 and data not shown).
|
Effect of NS1 on RNA synthesis from cDNA-encoded C2 minigenome or C4 mini-antigenome. We evaluated the effect of coexpression of the NS1 protein on the synthesis of positive-sense RNA from the C2 minigenome (Fig. 3A and B) or the synthesis of negative-sense RNA from the C4 mini-antigenome (Fig. 3C and D). The plasmid-supplied C2 or C4 minireplicon was complemented by the N, P, and L plasmids with or without the M2(1+2) plasmid (i.e., that containing both ORFs in their natural configuration). In previous work, the transcription elongation activity of ORF1 predominated in situations where smaller amounts of this plasmid (no more than 20% of that of the N plasmid) were transfected whereas the inhibitory activity associated with ORF2 predominated at higher plasmid levels (9). The amount of M2(1+2) plasmid supplied here was 5% of that of the N plasmid.
|
NS1, lanes 3 and 5).
Treatment of the cell lysates with micrococcal nuclease prior to RNA
isolation degraded most of the mRNA, whereas the level of the
mini-antigenome was undiminished (lanes 4 and 6). This confirmed
the identity of the antigenome, allowed it to be detected
unambiguously, and confirmed that it was efficiently encapsidated
in the reconstituted system. When NS1 plasmid was included at 50 ng per
well, the synthesis of positive-sense RNA, including the
mini-antigenome, was reduced almost to background levels (Fig. 4, panel
+NS1).
|
The effect of the NS1 plasmid is dependent upon an intact NS1 ORF. It was necessary to determine whether the inhibition associated with the NS1 plasmid depended upon its ability to express NS1 protein, as might be expected, or whether the inhibitory effect might be an artifact of transfection of the NS1 plasmid or synthesis of NS1 mRNA. Regarding this last possibility, it should be noted that although the C2 minigenome does contain the upstream nontranslated region of the NS1 mRNA (Fig. 1), this sequence is not present in the NS1 support plasmid because the initiation codon is joined directly to the internal ribosome entry site (13). It therefore seemed unlikely that the inhibition associated with expression of the NS1 plasmid was due to hybrid arrest of the minigenome by NS1 RNA, but it was important to directly rule out possible artifactual effects.
The first and eighth codons of the NS1 ORF are potential AUG translational start sites, whereas the next AUG is at codon 80. To preclude synthesis of the NS1 protein from either upstream start site, 2 nt were deleted from codon 8, which shifted the reading frame such that the mutant ORF would terminate 3 codons later (Fig. 5A). Western blot analysis of transfected cells (Fig. 5B) confirmed that while the original plasmid produced NS1 protein in a dose-dependent manner (lanes 1 to 5), the mutant plasmid was silent for its synthesis (lanes 6 to 9). Increasing amounts of the wild-type or mutant plasmid were evaluated for their effect on the expression of CAT enzyme by the C2 minigenome complemented by the N, P, L, and M2(1+2) plasmids (Fig. 5C). The wild-type plasmid was strongly inhibitory to CAT expression, and the use of this sensitive assay system showed that the inhibitory effect was complete in this particular experiment at 30 ng of input NS1 plasmid. In contrast, cotransfection of the mutant plasmid had no effect on the expression of CAT.
|
NS1 does not interfere with encapsidation of the plasmid-supplied
minigenome.
We then examined whether the action of the NS1
protein was at the level of encapsidation by examining the ability of N
and P proteins to encapsidate the plasmid-supplied minigenome
(Fig. 6). Cells were transfected with
plasmids encoding the C2 minigenome and various combinations of
support plasmids with or without the addition of NS1 plasmid (Fig. 6,
panels +NS1 and NS1, respectively). Cell lysates were prepared,
incubated with micrococcal nuclease or mock treated, and processed for
RNA purification. RNA which was encapsidated would be protected from
degradation and thus detected. The RNA was analyzed by Northern blot
hybridization with a positive-sense probe, which would detect
plasmid-encoded minigenome produced by T7 RNA polymerase as
well as progeny minigenome produced by the RSV
polymerase.
|
NS1 and
+NS1). Incidently, the ability of unencapsidated minigenome RNA
to accumulate intracellularly appears to be a property of 293 cells,
because in HEp-2 cells it accumulates only when protected by
encapsidation (14). Inclusion of P in addition to N resulted
in the encapsidation of a fraction of the total plasmid-encoded
minigenome RNA (lane 4, both panels). Some of the
plasmid-supplied minigenome was in a somewhat larger form,
which appears to be stabilized by the presence of uncleaved ribozyme at
the 3' end (14, 17). Thus, while encapsidation of the
plasmid-encoded minigenome may or may not be a good model for
authentic RSV encapsidation, it does require both N and P, as is
thought to be the case in the authentic situation. Importantly, the
amount of micrococcal nuclease-resistant genomic RNA was approximately
the same in both the absence and presence of the NS1 protein (lane 4, both panels), indicating that NS1 did not prevent the formation of the
encapsidated template. When L was included in addition to N and P and
in the absence of NS1, thus providing all of the components of the RSV
replicase, the encapsidated RNA was amplified 10- to 50-fold, depending
on the experiment (panel NS1, compare lane 6 with lane 4). Inclusion of the NS1 plasmid blocked this amplification (panel +NS1, lane 6), and
the presence of the M2(1+2) plasmid made no difference (lane 8).
These experiments showed that NS1 did not prevent the formation of the
encapsidated template but prevented its subsequent utilization by the
polymerase.
Effect of NS1 on the sequential transcription of successive small genes of a minigenome restricted to a single step in RNA replication. The experiment shown in Fig. 6 showed that reconstituted RNA replication involved extensive amplification of the plasmid-supplied minireplicon by the RSV polymerase. This complicated the analysis of the effects of NS1. For example, since most of the encapsidated minigenome which is available as a template for transcription is the product of the reconstituted RSV polymerase, it is difficult to know whether reduced accumulation of mRNA was due to a direct effect on transcription or was an indirect effect of reduced template availability because of reduced RNA replication. With regard to RNA replication, it is difficult to know whether inhibition was due to an effect on the synthesis of the genome or the antigenome or both.
We recently found that the ability of the minigenome to execute multiple rounds of RNA replication can be blocked by certain nucleotide substitutions in the trailer region, such as changing the fifth nucleotide from the 5' end from G to A (mutation TrG5A), or the seventh nucleotide from the 5' end from A to C (mutation TrA7C) (14, 25a). These mutations probably inactivate the promoter at the 3' end of the encoded mini-antigenome. Consistent with this, they did not affect the encapsidation of the T7-produced minigenome and did not reduce the amount of positive-strand RNA made per amount of encapsidated minigenome template. However, the synthesis of progeny minigenome was severely inhibited. Therefore, we analyzed the effect of NS1 on RNA synthesis by one of these mutants, MP13, which is a version of the C2 minigenome which contains the above-mentioned TrG5A mutation (Fig. 1) and would allow a direct examination of the effects on transcription. In addition, MP13 contains the insertion of a gene junction cassette into the BspEI site in the CAT ORF such that it encodes two subgenic CAT mRNAs of 271 and 495 nt (see Materials and Methods (Fig. 1). This has two advantages: (i) the mini-antigenome can be clearly distinguished from mRNA, and (ii) it was possible to investigate whether NS1 affected the gradient of transcription of these two small genes. Complementation of MP13 with N, P and L resulted in the synthesis of antigenome and the two subgenic CAT mRNAs (Fig. 7A, lane 2). The inclusion of increasing amounts of the NS1 plasmid resulted in a dose-dependent decrease in the synthesis of the mini-antigenome and mRNAs 1 and 2 (lanes 3 to 10). The presence of the M2(1+2) plasmid made little difference (data not shown). PhosphorImager analysis indicated that the effect of NS1 was similar for antigenome, mRNA 1 or mRNA 2 (Fig. 7B). This provided evidence that (i) the synthesis of all positive-sense RNAs was directly inhibited by NS1, (ii) the synthesis of mRNA (i.e., transcription) and the synthesis of the mini-antigenome (i.e., replication) were equally affected, and (iii) the gradient of transcriptional polarity was not altered detectably.
|
Effect of NS1 on the antigenomic promoter. As described above, the use of the mutant minigenome MP13, which is restricted to the synthesis of positive-sense RNA, made it possible to directly analyze the effect of NS1 on the genomic promoter. It also was of interest to test whether NS1 has an effect on synthesis from the antigenomic promoter. Therefore, we constructed a minigenome, MP123, in which the 3'-terminal 34 nt of the leader region were removed and replaced with the 3'-terminal 57 nt of the antigenome (Fig. 1), resulting in a copyback-type minireplicon. Since the 3' end of the antigenome is encoded by the minigenome trailer, it is referred to as the trailer complement. In addition, MP123 contained the A-to-C substitution at position 7 relative to the 5' end (TrA7C), a change which has an effect similar to that of the TrG5A mutation described above for MP13 and MP25 and greatly restricts amplification by the RSV polymerase. As a control, MP123 was compared with MP96 (see Materials and Methods), which is a version of the standard C2 minigenome which also contains the TrA7C mutation.
When complemented by N, P, L, and M2-1, MP123 directed the synthesis of the antigenome and polyadenylated subgenomic mRNA (Fig. 8C, lane 2). It is noteworthy that a copyback RSV minireplicon can direct the synthesis of mRNA, and the characterization of this activity will be described in greater detail elsewhere (25b). The identification of the antigenome was complicated by the fact that a background band of that size accumulated in the absence of the L protein (Fig. 8C, lane 1). However, when the cell lysates were treated with micrococcal nuclease before RNA purification, the background band was destroyed (Fig. 8D, lane 1), as was most of the mRNA (Fig. 8D, lane 2). Similar results were obtained with the MP96 minigenome analyzed in parallel (Fig. 8A and B), except that a background band was not observed in the absence of L protein (lanes 1). The addition of increasing amounts of NS1 inhibited the synthesis of positive-sense RNA by MP123 and MP96, and the magnitude of the effect appeared to be similar for the two minigenomes, with regard to both mRNA and the mini-antigenome. The effect on the mini-antigenome was seen most clearly with the micrococcal nuclease-treated samples (Fig. 8B and D). Thus, the synthesis of RNA from the genome and antigenome promoters was equally sensitive to the NS1 protein.
|
The inhibitory effect of NS1 on transcription is not affected by the expression of other RSV proteins. We considered the possibility that the inhibitory effect of coexpression of NS1 in the reconstituted transcription-replication system was an artifact due to the absence of one or more other viral proteins. We therefore tested whether various combinations and concentrations of the M2-1, M, SH, G, F, and NS2 plasmids might relieve the inhibitory activity of NS1. None of these, alone or in combination, did so (data not shown).
These studies did show that coexpression of the NS2 protein in the reconstituted system also inhibited RSV transcription and RNA replication whereas none of the remaining RSV proteins had an effect (data not shown). However, compared to NS1, much larger amounts of the input NS2 plasmid were needed for the equivalent level of inhibition of transcription and replication. Western blotting showed that substantial inhibition of transcription and RNA replication was possible only with amounts of expressed NS2 protein that were in considerable excess of that found in RSV-infected cells. The requirement for high levels of NS2 protein expression raised doubts about the authenticity of the NS2 effect, and it is being characterized further. The effects of NS1 and NS2 together were additive rather than synergistic, suggesting that the two proteins do not function together (unpublished data).| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
In this study, we investigated the effect of the RSV NS1 protein on transcription and RNA replication of the RSV minigenome and mini-antigenome analogs executed by plasmid-encoded proteins. Coexpression of the NS1 protein was highly inhibitory to both transcription and RNA replication. Both processes were affected equally, with 7 to 10 ng of input NS1 plasmid resulting in a reduction to 33% activity (Fig. 3). This level of expression of NS1 protein was well below the limit of detection by Western blot analysis. In RSV-infected cells, in comparison, the expression of NS1 was readily detected by 8 h postinfection. A 100-ng sample of transfected NS1 plasmid was required to achieve levels comparable to the levels observed in RSV-infected cells 20 h postinfection, when viral protein synthesis is maximal (Fig. 2). That the inhibitory effect of NS1 was associated with levels of protein equal or below those of RSV-infected cells suggested that the effect is an authentic one which could also operate during RSV infection.
Somewhat unexpectedly, the effect was not completely specific to RSV. Coexpression of NS1 also inhibited CAT expression by a minigenome analog of parainfluenza virus type 3 (PIV3) complemented by plasmid-expressed PIV3 N, P, and L proteins (12, 27a). However, the magnitude of the inhibition was at least 10-fold lower than that observed for RSV and thus occurred only at relatively high levels of NS1 expression. It is difficult to directly compare the two heterologous systems: each involves the expression of a number of components, none of which are in common, except for the CAT marker enzyme. Thus, there is no basis for standardization except that the two systems are similar in activity with regard to the production of CAT RNA and enzyme (reference 12 and data not shown). The finding that the magnitude of the inhibitory effect of NS1 was more than 10-fold greater with RSV than with PIV3 suggests that most of the effect is specific to RSV. There also might be some aspect that is common to RSV and PIV3. For example, the NS1 protein might bind to an RSV RNA or protein with a specificity that has some overlap with a PIV3 component, or part of its action might involve cellular components that both viruses use. Therefore, the inhibitory action of NS1 against PIV3 is not necessarily an artifact.
The results shown here did rule out certain trivial possibilities as causing the effect of NS1. The inhibitory effect of the NS1 plasmid was shown to depend on the presence of an intact NS1 ORF, evidence that the effect was mediated by NS1 protein rather than plasmid or RNA (Fig. 5). The synthesis of other RSV proteins from T7 expression plasmids was unaffected by coexpression of NS1 (Fig. 2 and unpublished data). The synthesis and encapsidation of plasmid-derived minigenome also were unaffected (Fig. 6). Thus, the effect of NS1 cannot be ascribed to perturbation or inhibition of plasmid transfection, synthesis of T7 polymerase by vaccinia virus, T7-mediated transcription, or translation and stability of plasmid-encoded RNA and protein. The inhibition mediated by NS1 also was not mitigated by coexpression of other RSV proteins.
We investigated which steps in RSV transcription and RNA replication might be affected by the NS1 protein. The finding that encapsidation of the plasmid-supplied minigenome was unaffected (Fig. 6) implied that the effect was at a later step. To determine whether the effect was at the level of RNA synthesis from the genome or antigenome, we used minireplicons that were engineered to contain either the genomic (MP13 and MP96) or the antigenomic (MP123) promoter at the 3' end. An important feature of these minireplicons is that they also contain a point substitution, either TrG5A or TrA7C, in the trailer region. Both mutations blocked most of the amplification by the RSV polymerase, limiting the available template to that supplied from the plasmid. These trailer point mutations will be described in greater detail elsewhere (25a). They do not interfere with the ability of the plasmid-supplied minigenome to be encapsidated and function as a template for the synthesis of mRNA and the mini-antigenome. The mini-antigenome which is produced is also encapsidated but is impaired as template for the synthesis of progeny minigenome. Thus, RNA synthesis is limited to the promoter at the 3' end of the plasmid-supplied template, allowing it to be examined in isolation. The results confirmed that NS1 affects both transcription and RNA replication and showed that the genomic and antigenomic promoters are equally affected.
Transcription by nonsegmented negative-strand viruses is polar, so that promoter-proximal genes are transcribed more frequently than are promoter-distal ones. This appears to be due to polymerase fall-off, which was shown to take place at the intergenic regions for the four shorter genes of vesicular stomatitis virus (19). The possibility that NS1 affected the gradient of transcriptional polarity was investigated by using two dicistronic minigenomes, MP13 and RSV-CAT-LUC(CAT), which contain dicistronic transcriptional units of 0.73 and 2.6 kb, respectively (Fig. 7) (data not shown). In each case, the upstream and downstream mRNAs were equally sensitive to inhibition by NS1, indicating that the polarity of gene transcription was unaffected. Thus, NS1 did not appear to affect chain elongation by the polymerase or its recognition and utilization of transcription signals. Also, the effect of NS1 protein on transcription was not altered by the presence or absence of the M2 plasmid, supplied either in the form of the first ORF alone, which encodes the transcription elongation factor, or in the form with the two ORFs in their natural configuration.
Taken together, these observations indicate that the NS1 protein acts at a stage after encapsidation but before sequential transcription. Since transcription and replication are equally strongly affected and since the two processes are thought to use the same promoter, it seems likely that NS1 acts at a common, early stage such as initiation at the genomic (and antigenomic) promoter. It remains to be determined whether NS1 acts on the encapsidated template or the polymerase. The latter possibility is suggested by the observation that 50% inhibition occurred with a concentration of the NS1 plasmid which is equimolar with the L plasmid but approximately 34- and 24-fold, respectively, lower than the molar concentrations of the N and P plasmids. However, 100% inhibition was observed only at a 20- to 25-fold molar excess of the NS1 plasmid relative to that of L.
The regulation of RNA synthesis by nonsegmented negative-strand RNA viruses is more complex than was previously appreciated. For example, (i) the RSV M2 mRNA encodes both a transcription elongation factor from its upstream ORF and a negative regulatory factor from its downstream ORF (9); (ii) the Sendai virus V protein inhibits the replication of a defective interfering (DI) genome, probably by interfering with either formation or use of the NP0-P encapsidation substrate (18); and (iii) the Sendai virus C proteins strongly inhibit the amplification of an internal deletion type of DI genome as well as of a complete infectious genome. However, C had no effect on the replication of a copyback-type DI genome or of an infectious genome that had been engineered to contain the antigenome promoter in place of the genome promoter (3). Hence, the C proteins appear to have a negative regulatory activity specific to the genomic promoter. Other studies also suggested that the Sendai virus C protein might be involved in down-regulating viral mRNA synthesis (11). Somewhat surprisingly, Sendai virus appears to require the expression of at least some form of C protein to be infectious (3), whereas the C protein of measles virus can be silenced without ablating infectivity (27). The inhibition caused by RSV NS1 seems to be different from that caused by the Sendai virus V and C proteins, because RSV NS1 did not interfere with encapsidation and was not promoter-specific.
The data described here strongly suggest that NS1 plays a role as a negative regulatory protein. The NS1 mRNA, encoded in the promoter-proximal gene, is the most abundant of the 10 mRNAs. A careful quantitation of the relative levels of NS1 protein expression during RSV infection has not yet been reported, but it is among the most highly expressed proteins. The potent inhibitory effects of NS1 would seem to be counterproductive for viral replication, especially during the early stages of infection, and thus it is difficult to envision what role this function might play in the RSV growth cycle. But the same comment can be made for the Sendai virus C protein, for example. It is likely that the apparent anomaly simply reflects the incomplete state of our understanding of the functions of these putative regulatory proteins. In addition, there is evidence that the NS1 protein is subject to posttranslational modification (10), which might temper its negative regulatory activity. The constant production of an unstable negative regulatory activity could be part of the reason why RSV replication and gene expression are slower and less productive than is the case for many other nonsegmented negative-strand RNA viruses.
Whether or not NS1 is a potent negative regulatory factor in a natural RSV infection, the finding that it inhibits minigenome RNA synthesis suggests that it interacts with components involved in that process. It will be of interest to examine whether RSV RNA synthesis and growth are affected in cell lines expressing the NS1 protein and to determine whether expression of the NS1 gene can be ablated or reduced in cDNA-encoded infectious virus (8) without compromising viral infectivity. Additional functional roles might also exist for the NS1 protein, such as in virion morphogenesis, interaction with the host cell, or interaction with innate or induced aspects of the host immune system.
| |
ACKNOWLEDGMENTS |
|---|
We thank Ena Camargo for performing the cell culture, Myron Hill for synthesizing and sequencing oligonucleotides, Juan Cristina for synthesizing riboprobes, and Michael Teng, Mario Skiadopoulos, and Anna Durbin for testing the effect of NS1 on the PIV3 minigenome. We also thank Siba Samal and Rachel Fearns for helpful discussions.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 7 Center Dr., MSC 0720, Bethesda, MD 20892-0720. Phone: (301) 496-3481. Fax: (301) 496-8312. E-mail: pcollins{at}atlas.niaid.nih.gov.
Present address: Division of Viral Products, CBER, FDA, Bethesda,
MD 20892.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References
|
|---|
| 1. |
Alansari, H., and L. N. D. Potgeiter.
1994.
Nucleotide and predicted amino acid sequence analysis of the ovine respiratory syncytial virus nonstructural 1C and 1B genes and the small hydrophobic protein gene.
J. Gen. Virol.
75:401-404 |
| 2. |
Baker, S. C., and S. A. Moyer.
1988.
Encapsidation of Sendai virus genome RNAs by purified NP protein during in vitro replication.
J. Virol.
62:834-838 |
| 3. |
Cadd, T.,
D. Garcin,
C. Tapparel,
M. Itoh,
M. Homma,
L. Roux,
J. Curran, and D. Kolakofsky.
1996.
The Sendai paramyxovirus accessory C proteins inhibit viral genome amplification in a promoter-specific fashion.
J. Virol.
70:5067-5074 |
| 4. | Chomczynski, P. 1992. One hour downward alkaline capillary transfer for blotting of DNA and RNA. Anal. Biochem. 20:134-139. |
| 5. |
Collins, P. L., and G. W. Wertz.
1983.
cDNA cloning and transcriptional mapping of nine polyadenylated RNAs encoded by the genome of human respiratory syncytial virus.
Proc. Natl. Acad. Sci. USA
80:3208-3212 |
| 6. | Collins, P. L., and G. W. Wertz. 1985. Nucleotide sequences of the 1B and 1C nonstructural protein mRNAs of human respiratory syncytial virus. Virology 143:442-451[Medline]. |
| 7. | Collins, P. L. 1991. The molecular biology of human respiratory syncytial virus (RSV) of genus Pneumovirus, p. 103-162. In D. W. Kingsbury (ed.), The paramyxoviruses. Plenum Publishing Corp., New York, N.Y. |
| 8. |
Collins, P. L.,
M. G. Hill,
E. Camargo,
H. Grosfeld,
R. M. Chanock, and B. R. Murphy.
1995.
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the M2 (ORF1) transcription elongation factor in gene expression and provides a new capability for vaccine development.
Proc. Natl. Acad. Sci. USA
92:11563-11567 |
| 9. |
Collins, P. L.,
M. G. Hill,
J. Cristina, and H. Grosfeld.
1996.
Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus.
Proc. Natl. Acad. Sci. USA
93:81-85 |
| 10. | Collins, P. L., K. McIntosh, and R. M. Chanock. 1996. Respiratory syncytial virus, p. 1313-1352. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed. Raven Press, New York, N.Y. |
| 11. | Curran, J., J.-B. Marq, and D. Kolakofsky. 1992. The Sendai virus nonstructural C proteins specifically inhibit viral mRNA synthesis. Virology 189:647-656[Medline]. |
| 12. | Durbin, A. P., J. W. Siew, B. R. Murphy, and P. L. Collins. 1997. Minimum requirements for transcription and RNA replication of a minigenome of human parainfluenza virus type 3. Virology 234:74-83[Medline]. |
| 13. |
Elroy-Stein, O,
T. R. Fuerst, and B. Moss.
1989.
Cap-independent translation of mRNA conferred by encephalomyocarditis virus 5' sequence improves the performance of the vaccinia virus/bacteriophage T7 hybrid system.
Proc. Natl. Acad. Sci. USA
86:6126-6130 |
| 14. | Fearns, R., M. E. Peeples, and P. L. Collins. 1997. Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome. Virology 236:188-201[Medline]. |
| 15. |
Fuerst, T. R.,
E. G. Niles,
F. W. Studier, and B. Moss.
1986.
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase.
Proc. Natl. Acad. Sci. USA
83:8122-8126 |
| 16. |
Gorman, C. M.,
L. F. Moffat, and B. H. Howard.
1982.
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
Mol. Cell. Biol.
2:1044-1051 |
| 17. | Grosfeld, H., M. G. Hill, and P. L. Collins. 1995. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins: transcription also occurs under these conditions but required RSV superinfection for efficient synthesis of full-length mRNA. J. Virol. 69:5677-5686[Abstract]. |
| 18. | Horikami, S., S. Smallwood, and S. Moyer. 1996. The Sendai virus V protein interacts with the NP protein to regulate viral genome RNA replication. Virology 222:383-390[Medline]. |
| 19. | Iverson, L. E., and J. K. Rose. 1981. Localized attenuation and discontinuous synthesis during vesicular stomatitis virus transcription. Cell 23:477-484[Medline]. |
| 20. |
Johnson, P. R., and P. L. Collins.
1989.
The 1B (NS2), 1C (NS1) and N proteins of human respiratory syncytial virus (RSV) of antigenic subgroups A and B: sequence conservation and divergence within RSV genomic RNA.
J. Gen. Virol.
70:1539-1547 |
| 21. |
Kuo, L.,
H. Grosfeld,
J. Cristina,
M. G. Hill, and P. L. Collins.
1996.
Effect of Mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus.
J. Virol.
70:6892-6901 |
| 22. | Kuo, L., R. Fearns, and P. L. Collins. 1996. The structurally diverse intergenic regions of respiratory syncytial virus do not modulate sequential transcription by a dicistronic minigenome. J. Virol. 70:6143-6150[Abstract]. |
| 23. | Kuo, L., R. Fearns, and P. L. Collins. 1997. Analysis of the gene start and gene end signals of human respiratory syncytial virus: quasi-templated initiation at position 1 of the encoded mRNA. J. Virol. 71:4944-4953[Abstract]. |
| 24. | Lamb, R. A., and D. Kolakofsky. 1996. Paramyxoviridae: the viruses and their replication, p. 1177-1204. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed. Raven Press, New York, N.Y. |
| 25. |
Patsey, M., and S. K. Samal.
1995.
Nucleotide sequence analysis of the non-structural NS1 (1C) and NS2 (1B) protein genes of bovine respiratory syncytial virus.
J. Gen. Virol.
76:193-197 |
| 25a. | Peeples, M. E., R. Fearns, J. Cristina, and P. L. Collins. Unpublished data. |
| 25b. | Peeples, M. E., R. Fearns, and P. L. Collins. Unpublished data. |
| 26. | Perotta, A. T., and M. D. Been. 1991. A pseudoknot-like structure required for efficient self-cleavage of hepatitis delta virus RNA. Nature 350:434-436[Medline]. |
| 27. | Radecke, F., and M. A. Billeter. 1996. The nonstructural C protein is not essential for multiplication of Edmonston B strain measles virus in cultured cells. Virology 217:418-421[Medline]. |
| 27a. | Teng, M., A. Durbin, and M. Skiadopoulos. Unpublished data. |
| 28. |
Towbin, H.,
R. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedures and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354 |
| 29. | Wagner, R. R., and J. K. Rose. 1996. Rhabdoviridae and their replication, p. 1121-1135. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed. Raven Press, New York, N.Y. |
J Virol, February 1998, p. 1452-1461, Vol. 72, No. 2
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Swedan, S., Musiyenko, A., Barik, S.
(2009). Respiratory Syncytial Virus Nonstructural Proteins Decrease Levels of Multiple Members of the Cellular Interferon Pathways. J. Virol.
83: 9682-9693
[Abstract] [Full Text] -
Ling, Z., Tran, K. C., Teng, M. N.
(2009). Human Respiratory Syncytial Virus Nonstructural Protein NS2 Antagonizes the Activation of Beta Interferon Transcription by Interacting with RIG-I. J. Virol.
83: 3734-3742
[Abstract] [Full Text] -
Sleeman, K., Bankamp, B., Hummel, K. B., Lo, M. K., Bellini, W. J., Rota, P. A.
(2008). The C, V and W proteins of Nipah virus inhibit minigenome replication. J. Gen. Virol.
89: 1300-1308
[Abstract] [Full Text] -
Bitko, V., Shulyayeva, O., Mazumder, B., Musiyenko, A., Ramaswamy, M., Look, D. C., Barik, S.
(2007). Nonstructural Proteins of Respiratory Syncytial Virus Suppress Premature Apoptosis by an NF-{kappa}B-Dependent, Interferon-Independent Mechanism and Facilitate Virus Growth. J. Virol.
81: 1786-1795
[Abstract] [Full Text] -
Kotelkin, A., Belyakov, I. M., Yang, L., Berzofsky, J. A., Collins, P. L., Bukreyev, A.
(2006). The NS2 Protein of Human Respiratory Syncytial Virus Suppresses the Cytotoxic T-Cell Response as a Consequence of Suppressing the Type I Interferon Response.. J. Virol.
80: 5958-5967
[Abstract] [Full Text] -
Schneider, U., Blechschmidt, K., Schwemmle, M., Staeheli, P.
(2004). Overlap of Interaction Domains Indicates a Central Role of the P Protein in Assembly and Regulation of the Borna Disease Virus Polymerase Complex. J. Biol. Chem.
279: 55290-55296
[Abstract] [Full Text] -
Easton, A. J., Domachowske, J. B., Rosenberg, H. F.
(2004). Animal Pneumoviruses: Molecular Genetics and Pathogenesis. Clin. Microbiol. Rev.
17: 390-412
[Abstract] [Full Text] -
Cornu, T. I., Feldmann, H., de la Torre, J. C.
(2004). Cells Expressing the RING Finger Z Protein Are Resistant to Arenavirus Infection. J. Virol.
78: 2979-2983
[Abstract] [Full Text] -
Tran, K. C., Collins, P. L., Teng, M. N.
(2004). Effects of Altering the Transcription Termination Signals of Respiratory Syncytial Virus on Viral Gene Expression and Growth In Vitro and In Vivo. J. Virol.
78: 692-699
[Abstract] [Full Text] -
Perez, M., Sanchez, A., Cubitt, B., Rosario, D., de la Torre, J. C.
(2003). A reverse genetics system for Borna disease virus. J. Gen. Virol.
84: 3099-3104
[Abstract] [Full Text] -
Schneider, U., Naegele, M., Staeheli, P., Schwemmle, M.
(2003). Active Borna Disease Virus Polymerase Complex Requires a Distinct Nucleoprotein-to-Phosphoprotein Ratio but No Viral X Protein. J. Virol.
77: 11781-11789
[Abstract] [Full Text] -
Bossert, B., Marozin, S., Conzelmann, K.-K.
(2003). Nonstructural Proteins NS1 and NS2 of Bovine Respiratory Syncytial Virus Block Activation of Interferon Regulatory Factor 3. J. Virol.
77: 8661-8668
[Abstract] [Full Text] -
Valarcher, J.-F., Furze, J., Wyld, S., Cook, R., Conzelmann, K.-K., Taylor, G.
(2003). Role of Alpha/Beta Interferons in the Attenuation and Immunogenicity of Recombinant Bovine Respiratory Syncytial Viruses Lacking NS Proteins. J. Virol.
77: 8426-8439
[Abstract] [Full Text] -
Blakqori, G., Kochs, G., Haller, O., Weber, F.
(2003). Functional L polymerase of La Crosse virus allows in vivo reconstitution of recombinant nucleocapsids. J. Gen. Virol.
84: 1207-1214
[Abstract] [Full Text] -
Neumann, G., Whitt, M. A., Kawaoka, Y.
(2002). A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?. J. Gen. Virol.
83: 2635-2662
[Abstract] [Full Text] -
Krempl, C., Murphy, B. R., Collins, P. L.
(2002). Recombinant Respiratory Syncytial Virus with the G and F Genes Shifted to the Promoter-Proximal Positions. J. Virol.
76: 11931-11942
[Abstract] [Full Text] -
Ghildyal, R., Mills, J., Murray, M., Vardaxis, N., Meanger, J.
(2002). Respiratory syncytial virus matrix protein associates with nucleocapsids in infected cells. J. Gen. Virol.
83: 753-757
[Abstract] [Full Text] -
Bossert, B., Conzelmann, K.-K.
(2002). Respiratory Syncytial Virus (RSV) Nonstructural (NS) Proteins as Host Range Determinants: a Chimeric Bovine RSV with NS Genes from Human RSV Is Attenuated in Interferon-Competent Bovine Cells. J. Virol.
76: 4287-4293
[Abstract] [Full Text] -
Lu, B., Brazas, R., Ma, C.-H., Kristoff, T., Cheng, X., Jin, H.
(2002). Identification of Temperature-Sensitive Mutations in the Phosphoprotein of Respiratory Syncytial Virus That Are Likely Involved in Its Interaction with the Nucleoprotein. J. Virol.
76: 2871-2880
[Abstract] [Full Text] -
Fearns, R., Peeples, M. E., Collins, P. L.
(2002). Mapping the Transcription and Replication Promoters of Respiratory Syncytial Virus. J. Virol.
76: 1663-1672
[Abstract] [Full Text] -
Lopez, N., Jacamo, R., Franze-Fernandez, M. T.
(2001). Transcription and RNA Replication of Tacaribe Virus Genome and Antigenome Analogs Require N and L Proteins: Z Protein Is an Inhibitor of These Processes. J. Virol.
75: 12241-12251
[Abstract] [Full Text] -
Cornu, T. I., de la Torre, J. C.
(2001). RING Finger Z Protein of Lymphocytic Choriomeningitis Virus (LCMV) Inhibits Transcription and RNA Replication of an LCMV S-Segment Minigenome. J. Virol.
75: 9415-9426
[Abstract] [Full Text] -
Marriott, A. C., Smith, J. M., Easton, A. J.
(2001). Fidelity of Leader and Trailer Sequence Usage by the Respiratory Syncytial Virus and Avian Pneumovirus Replication Complexes. J. Virol.
75: 6265-6272
[Abstract] [Full Text] -
Bullido, R., Gómez-Puertas, P., Saiz, M. J., Portela, A.
(2001). Influenza A Virus NEP (NS2 Protein) Downregulates RNA Synthesis of Model Template RNAs. J. Virol.
75: 4912-4917
[Abstract] [Full Text] -
Schlender, J., Bossert, B., Buchholz, U., Conzelmann, K.-K.
(2000). Bovine Respiratory Syncytial Virus Nonstructural Proteins NS1 and NS2 Cooperatively Antagonize Alpha/Beta Interferon-Induced Antiviral Response. J. Virol.
74: 8234-8242
[Abstract] [Full Text] -
Fearns, R., Collins, P. L., Peeples, M. E.
(2000). Functional Analysis of the Genomic and Antigenomic Promoters of Human Respiratory Syncytial Virus. J. Virol.
74: 6006-6014
[Abstract] [Full Text] -
Lee, K. J., Novella, I. S., Teng, M. N., Oldstone, M. B. A., de la Torre, J. C.
(2000). NP and L Proteins of Lymphocytic Choriomeningitis Virus (LCMV) Are Sufficient for Efficient Transcription and Replication of LCMV Genomic RNA Analogs. J. Virol.
74: 3470-3477
[Abstract] [Full Text] -
Jin, H., Cheng, X., Zhou, H. Z. Y., Li, S., Seddiqui, A.
(2000). Respiratory Syncytial Virus That Lacks Open Reading Frame 2 of the M2 Gene (M2-2) Has Altered Growth Characteristics and Is Attenuated in Rodents. J. Virol.
74: 74-82
[Abstract] [Full Text] -
Bermingham, A., Collins, P. L.
(1999). The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc. Natl. Acad. Sci. USA
96: 11259-11264
[Abstract] [Full Text] -
Fearns, R., Collins, P. L.
(1999). Role of the M2-1 Transcription Antitermination Protein of Respiratory Syncytial Virus in Sequential Transcription. J. Virol.
73: 5852-5864
[Abstract] [Full Text] -
Whitehead, S. S., Bukreyev, A., Teng, M. N., Firestone, C.-Y., St. Claire, M., Elkins, W. R., Collins, P. L., Murphy, B. R.
(1999). Recombinant Respiratory Syncytial Virus Bearing a Deletion of either the NS2 or SH Gene Is Attenuated in Chimpanzees. J. Virol.
73: 3438-3442
[Abstract] [Full Text] -
Buchholz, U. J., Finke, S., Conzelmann, K.-K.
(1999). Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter. J. Virol.
73: 251-259
[Abstract] [Full Text] -
Teng, M. N., Collins, P. L.
(1999). Altered Growth Characteristics of Recombinant Respiratory Syncytial Viruses Which Do Not Produce NS2 Protein. J. Virol.
73: 466-473
[Abstract] [Full Text] -
Teng, M. N., Collins, P. L.
(1998). Identification of the Respiratory Syncytial Virus Proteins Required for Formation and Passage of Helper-Dependent Infectious Particles. J. Virol.
72: 5707-5716
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»